Gilead Sciences stock gets a two-year oncology deal extension

Published on 10/05/2026 at 22:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock was last at USD 144.63 on October 5, 2026, as a two-year oncology research extension added a fresh business update. Q2 revenue rose 10.6 percent to USD 7.80 billion.

Photorealistischer Biotech-Campus von Gilead Sciences mit Glaslabor und Wissenschaftlern — Gilead Sciences Forschungscampus mit ISIN US3755581036 modernes Biopharma-Labor Kalifornien Glasfassade Wissenschaftler arbeiten, Illustration mit AI erstellt.

Gilead Sciences (ISIN US3755581036) was last at USD 144.63 on Nasdaq at 4:00 p.m. ET on October 5, 2026, while the company extended an oncology research collaboration with Nurix for two years. The agreement covers an undisclosed program and adds a fresh development angle to Gilead's pipeline.

Two years added to oncology work

According to Business Insider on October 5, 2026, Nurix and Gilead agreed to extend the research term for an oncology program by two years. The extension is the second two-year renewal of the program, which began under the companies' strategic collaboration in 2019.

The financial importance is still undefined because the program remains undisclosed, but the agreement keeps Gilead connected to targeted protein degradation research. That matters alongside the company's larger oncology push through Trodelvy, cell therapy and acquired research platforms.

Q2 growth meets a major charge

Gilead's second-quarter 2026 revenue was USD 7.80 billion, up 10.6 percent year over year and above the USD 7.40 billion consensus estimate, according to MarketBeat. Non-GAAP EPS was USD -6.75 against consensus of USD -7.25, a USD 0.50 beat.

The headline earnings loss needs context. In the Q2 call dated August 4, 2026, Fortune reported that quarterly PrEP sales doubled year over year and exceeded USD 1 billion, while full-year HIV growth guidance increased to 9 percent to 10 percent from 8 percent. The call also described base business sales of USD 7.6 billion, up 10 percent year over year.

Analyst targets stay above the price

Consensus remains Moderate Buy, with 23 Buy ratings and six Hold ratings and an average price target of USD 158.78, according to MarketBeat. A separate Yahoo Finance overview lists a USD 123.00 low target, a USD 158.65 average and a USD 180.00 high target.

At USD 144.63, the average target of USD 158.65 lies 9.7 percent above the price. The spread reflects a market weighing strong HIV execution and pipeline expansion against acquisition-related charges and pressure in parts of the cell-therapy portfolio.

Gilead Sciences stock holds a broad range

Gilead Sciences stock was last at USD 144.63 on Nasdaq on October 5, 2026, down 0.08 percent from the prior session. The session range was USD 142.79 to USD 145.16, volume reached 4,522,219 shares, and the 52-week range was USD 112.41 to USD 157.29.